Febrile Neutropenia & Patient Access to Care
- Austin, Texas — Patients undergoing chemotherapy who face transportation barriers may experience higher rates of febrile neutropenia (FN), a common and serious complication.
- The study retrospectively reviewed patient charts, comparing FN rates within 20 days of chemotherapy in those with and without transportation challenges.
- The research compared FN rates in patients receiving CSFs during inpatient admission, dividing them into two groups based on the presence or absence of transportation barriers.
Transportation barriers significantly impact febrile neutropenia (FN) rates in chemotherapy patients. New research to be presented at the 2025 OPC meeting reveals a crucial link between transportation challenges and increased FN, a serious chemo complication. The study highlights how these barriers, acting as a health-related social need, may influence the effectiveness of FN prevention strategies. Notably, findings suggest pegfilgrastim could offer improved protection for those facing transportation difficulties. This vital facts underscores the primary_keyword the role of social determinants of health in cancer care. News Directory 3 reports these findings, which prompt further inquiry into FN and the secondary_keyword impact of accessibility. Discover whatS next for enhancing patient outcomes.
transportation Barriers Impact Chemo Patients’ Role in FN Prevention
Updated june 17, 2025
Austin, Texas — Patients undergoing chemotherapy who face transportation barriers may experience higher rates of febrile neutropenia (FN), a common and serious complication. Research exploring this link will be presented at the 2025 Oncology Pharmacists Connect (OPC) meeting in austin, Texas, from June 19-20.
The study retrospectively reviewed patient charts, comparing FN rates within 20 days of chemotherapy in those with and without transportation challenges. While colony-stimulating factors (CSFs) are typically used to mitigate severe FN, the study suggests that transportation barriers, a health-related social need (HRSN), may influence their effectiveness.
The research compared FN rates in patients receiving CSFs during inpatient admission, dividing them into two groups based on the presence or absence of transportation barriers. A secondary analysis compared FN rates between those receiving filgrastim versus pegfilgrastim within these groups and also examined the length of inpatient stays.
The study found a 67% difference in FN rate between pegfilgrastim and filgrastim in the group facing transportation barriers, suggesting pegfilgrastim may offer better FN prevention in these cases. Researchers emphasize the need for further investigation into how HRSNs impact outcomes for chemotherapy patients, highlighting the important role of social determinants of health.
The Hematology/Oncology Pharmacy Association (HOPA) BCOP Program will precede the OPC meeting on June 18. It will feature 4.0 CE hours from BCOP Updates 2024 and the Annual Conference 2025,covering topics like acute leukemia and cellular therapy.
What’s next
The presentation at the OPC meeting is expected to spur further research into the impact of health-related social needs on cancer treatment outcomes and the important role of pharmacists in addressing these challenges.